France: Sartorius Stedim Biotech acquires Xell for around €50m-plus

Life science company Sartorius Stedim Biotech has acquired cell culture specialist Germany-headquartered Xell for around €50m (US$58.6m) plus two earn-outs based on defined revenue targets for 2022 to 2025. Xell develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors used in gene therapeutics and vaccines. The company also…

You must be a HMI Subscriber to view this content.

Subscribe Now »